Skip to content
DataLookout
Menu

RFA-ADENO-USGNCT07906535

Ultrasound-Guided Radiofrequency Ablation for Focal Adenomyosis

StatusNot Yet Recruiting
PhaseNot applicable
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Change in pain severity (VAS) from baseline
Timeframe: Baseline, 6 months and 12 months after the procedure
Change in menstrual blood loss (PBAC score) from baseline
Timeframe: Baseline, 6 months and 12 months after the procedure

Secondary (5)

Change in EQ VAS (EQ-5D-5L) from baseline
Change in volume of the focal adenomyotic lesion and of the uterus on transvaginal ultrasound
Number of participants with adverse events and serious adverse events
Patient satisfaction and perceived change after the procedure
Proportion of participants requiring repeat treatment of adenomyosis or hysterectomy

Arms and interventions

RFA of focal adenomyosisExperimental

Transvaginal ultrasound-guided radiofrequency ablation of the focal adenomyotic lesion under general anesthesia using the Myoblate system (Mygen V-1000 generator). Follow-up visits with TVUS and questionnaires (VAS, PBAC, EQ-5D-5L) at 3, 6 and 12 months (optionally 24 months).

Devices: Myoblate Radiofrequency Ablation System (Mygen V-1000 generator)

Sites

1 site in 1 country

  • University Hospital PilsenPilsen, Czech Republic, Czechia